Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials

Ramzi EL Féghali[1]
Sophie Nisse-Durgeat[2]
Roland Asmar[1]

[1]The CardioVascular Institute, Paris, France; [2]Laboratoires Takeda, Puteaux, France

Objective: To study the effect of candesartan cilexetil (CC) in the management of blood pressure (BP) in diabetic and non-diabetic hypertensive patients.

Methods: A selection of five randomized double-blind clinical trials in which patients were treated for hypertension with CC was analyzed. All of these were similar in design: i) a 4-week placebo run-in period, ii) a 4- to 6-week period (V1) with CC 8 mg once daily (od), after which the dosage was doubled if BP was not normalized (BP >140/90 or BP >130/80 mmHg in diabetes), and iii) a 4- to 6-week period (V2) with CC 8 or 16 mg od. Efficacy was measured at V1 and V2.

Results: 702 patients were screened. The population consisted of 397 males (56.6%) with a mean age of 60 ± 11 years, with 153 diabetic (21.8%) and 549 non-diabetic (78.2%) patients. At baseline, mean BP values were 160/94/65 mmHg for SPB, DBP, and pulse pressure (PP) respectively, with differences between diabetic and non-diabetic patients. SBP, DBP, and PP values showed a significant reduction at V1 ($p < 0.001$) and V2 ($p < 0.001$) compared with baseline for all hypertensive patients. Mean changes at V2 in SBP and PP values were higher in diabetic than non-diabetic patients ($p < 0.001$), and to a lesser degree on DBP values ($p = 0.034$).

Conclusions: CC was effective in lowering BP in diabetic and non-diabetic hypertensive patients. CC is a promising therapy to manage hypertensive diabetic patients, as demonstrated by the significant BP reduction.

Keywords: candesartan cilexetil, hypertension, antihypertensive diabetes, blood pressure lowering, angiotensin II receptor antagonist

Short abstract: The effect of candesartan cilexetil (CC) on controlling blood pressure (BP) in hypertensive diabetic and non-diabetic patients was analyzed. Five randomized double-blind trials were pooled treating hypertension by CC (n = 702), including 153 diabetic (21.8%) and 549 non-diabetic (78.2%) patients. After treatment with CC (8–16 mg), significant reductions in SBP, DBP, and pulse pressure (PP) values were observed after 4–6 weeks ($p < 0.001$) and after 8–12 weeks ($p < 0.001$) compared with baseline for all hypertensive patients. Mean BP reductions after 8–12 weeks were higher in diabetic patients than non-diabetic ($p < 0.001$). CC is a promising therapy to treat hypertensive patients, both diabetic and non-diabetic.

Introduction

Essential hypertension is the most prevalent cardiovascular disease in the world, and a major public health issue. Its prevalence is increasing in the adult population, and is estimated to be 30% in developed countries (Asmar et al 2001; Guidelines Committee 2003). Arterial hypertension, in which insulin resistance is common, is strongly associated with type 2 diabetes. Diabetes mellitus is increasing rapidly worldwide, and since many patients with hypertension develop diabetes, this combination of risk factors will account for a large proportion of cardiovascular morbidity and mortality (HDSG 1993; Stamler et al 1993).

Correspondence: Roland Asmar
The CardioVascular Institute, 2, rue du Docteur Blanche, 75016 Paris, France
Tel +33 1 55 74 66 66
Fax +33 1 55 74 66 65
Email icv@icv.org

International Guidelines for the Management of Hypertension have emphasized that blood pressure (BP)-lowering therapy can reduce macrovascular disease for diabetic patients which may be more significant than blood glucose control (Staessen et al 1997). Results from different studies (Hansson et al 1998; UKPDS 33 1998; UKPDS 34 1998; UKPDS 38 1998) have demonstrated that aggressive lowering of diastolic BP (DPB) in diabetic patients was accompanied by reductions of macrovascular and microvascular events. In addition, the aggressive antihypertensive treatment of diabetic patients with systolic hypertension has been favored in some studies (SHEP Cooperative Research Group 1991; Bakris et al 2000; Chaudhry et al 2004).

Pharmacological agents recommended as initial therapy for diabetic patients include diuretics, β-blockers, angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, and angiotensin II blocker receptors (ARBs) (Guidelines Subcommittee 1999; Chobanian et al 2003). The choice of antihypertensive drug regimen in diabetic subjects is important for several reasons: they are susceptible to suffer metabolic decompensation, and the diabetic state may alter the pharmacokinetics of several cardiovascular drugs (Preston et al 2001). In this way, captopril was found superior to a diuretic/β-blocker antihypertensive treatment in diabetic patients, especially in those with metabolic decompensation (Niskanen et al 2001). Consequently, dosage requirements established for non-diabetic patients, when applied to the patient with diabetes, may potentially result in either therapeutic failure or undesirable adverse effects. Some epidemiological and clinical studies suggested a causal link between the use of thiazide diuretics and the subsequent development of type 2 diabetes (Bengtsson et al 1984; Padwal and Laupacis 2004), and β-blockers are not specifically indicated in diabetic patients (Scheen 2004). ACE inhibitors (Trost and Weidman 1987; Pollare et al 1989; Berne et al 1991; Oksa et al 1994; Padwal and Laupacis 2004; Scheen 2004) and calcium channel antagonists (Trost and Weidmann 1987; Padwal and Laupacis 2004; Scheen 2004) have little or no significant effects on plasma glucose and insulin levels in patients with and without diabetes.

ARBs have beneficial renal effects in patients with diabetes and nephropathy (Brenner et al 2001; Lewis et al 2001; Parving et al 2001; Lindholm et al 2002). A recent study demonstrated that a subset of angiotensin receptor antagonists (ARAs) induces peroxisome proliferators-activated receptor (PPARγ), providing a potential mechanism

for their insulin-sensitizing/antidiabetic effects (Scheen 2004) and an opportunity for the prevention and treatment of diabetes and cardiovascular disease in high-risk populations (Pershadsingh and Kurtz 2004). Among the ARBs, candesartan cilexetil (CC) is a potent, highly selective, angiotensin II type 1 (AT1) blocker receptor. Due to tight binding to and slow dissociation from the receptor, CC provides a strong, dose-dependent, and long-lasting antihypertensive effect. CC does not affect glucose homeostasis or the serum lipid profile (Trenwalder et al 1998), and is effective in reducing BP and microalbuminuria (Mogensen et al 2000) in hypertensive patients with type 2 diabetes. Five randomized double-blind studies (Denolle et al 2001; Imbs and Nisse-Durgeat 2005; Baguet et al 2006; Olivier JP, pers comm; Baguet JP, pers comm) demonstrated the efficacy of CC (8–16 mg) in controlling hypertensive patients. Whether this efficacy is similar in diabetic and non-diabetic patients is not yet established. The aim of this study was to analyze the effect of CC on BP in these two populations by pooling data from five randomized double-blind clinical trials (Denolle et al 2001; Imbs and Nisse-Durgeat 2005; Baguet et al 2006; Olivier JP, pers comm; Baguet JP, pers comm).

Materials and methods
Study population
This was a retrospective data meta-analysis of five randomized double-blind studies (Trenkwalder et al 1998; Mogensen et al 2000; Imbs and Nisse-Durgeat 2005; Baguet JP, pers comm; Olivier JP, pers comm) evaluating the efficacy of CC (8–16 mg). These five studies had a similar design: 2- to 4-week placebo wash out period, followed by 4- to 6-week double-blind period where patients received the active drug once daily. After this period, if BP was not normalized (SBP or DBP $\geq 140/90$ mmHg or $\geq 130/80$ mmHg in diabetes patients) the treatment could be doubled during another 4- to 6-week period. Efficacy was analyzed at V1 (after the first CC period treatment) and at V2 (after the second period treatment). A total of 702 patients treated by CC were included in this analysis.

Statistical analysis
All statistical analysis was undertaken using a Number Cruncher Statistical System (NCSS 2000, Kaysville, Utah, USA). Quantitative variables were expressed as mean $\pm$ SD, minimum and upper values, and were compared using a Student's t-test; a Wilcoxon test was performed if the data

were not normally distributed. Qualitative variables were expressed as absolute number and percentage values, and were analyzed using a Chi-square test.

Mean pressure values were compared before and after CC treatment in each group, and between groups (diabetic and non-diabetic patients) using a t-test. Final blood pressure (V1 and V2) comparison between diabetic and non-diabetic group was performed by a covariance analysis with and adjustment to the initial BP values and weight. P < 0.05 was considered statistically significant.

Results
Patients
The patient characteristics are presented in Table 1. This analysis included 702 hypertensive patients composed of two sub-groups: 153 of diabetic patients (21.8%) and 549 of non-diabetic patients (78.2%). Patients were principally men (57%), with 60 ± 11 years of age. Diabetic patients had higher weight values than non-diabetic patients. At baseline, systolic and diastolic blood pressure values were significantly higher in non-diabetic patients compared with diabetic (Table 1).

Antihypertensive effect of candesartan cilexetil
Blood pressure reduction in overall population
Changes of SBP, DBP, and pulse pressure (PP) values after CC treatment for all patients are shown in Figure 1. Blood pressure values showed a significant decrease at V1 and V2 following CC 8–16 mg treatments. In the global population significant reductions at V1 (p < 0.001) and V2 (p < 0.001) were found for SBP, DBP, and PP (Figure 1a). The most important change occurred between baseline and V1 (SBP/DBP/PP: –14/–9/–5 mmHg), but the BP values continued

to decrease up to V2 (SBP/DBP/PP: –18/–10/–7 mmHg), reaching final BP values of 141/83/58 mmHg for SBP, DBP, and PP respectively (Figure 1a). Mean changes in heart rate were not significant at V1 (–0.2 bpm) or at V2 (–1.1 bpm), reaching a final value of 72 bpm.

Blood pressure reduction in diabetic patients
In diabetic patients, significant reductions at V1 (p < 0.001) and V2 (p < 0.001) were found for SBP, DBP, and PP (Figure 1b). The most important change occurred between baseline and V1 (SBP/DBP/PP: –14/–9/–5 mmHg), but the BP values continued to decrease up to V2 (SBP/DBP/PP: –21/–11/–10 mmHg), reaching final BP values of 137/82/55 mmHg for SBP, DBP, and PP respectively (Figure 1b). Mean changes in heart rate were not significant at V1 (–0.3 bpm) or at V2 (–1.3 bpm), reaching a final value of 73 bpm.

Blood pressure reduction in non-diabetic patients
In non-diabetic patients, significant reductions at V1 (p < 0.001) and V2 (p < 0.001) were found for SBP, DBP, and PP (Figure 1c), with the most important change between baseline and V1 (SBP/DBP/PP: –14/–9/–5 mmHg), and a less pronounced decrease up to V2 (SBP/DBP/PP: –17/–11/–7 mmHg), reaching final BP values of 143/84/59 mmHg for SBP, DBP, and PP respectively (Figure 1c). Mean changes in heart rate were not significant at V1 (–0.2 bpm) or at V2 (–1 bpm), reaching a final value of 72 bpm.

Comparison of antihypertensive effect of CC in diabetic and non-diabetic patients
Table 2 compares mean changes of BP and heart rate values between diabetic and non-diabetic patients. At V1, the reductions observed in BP and heart rate values compared with baseline were similar for both diabetic and non-diabetic patients. At V2, the reductions observed in BP values

**Table 1** Baseline characteristics of patients

	Diabetic n = 153	Non-diabetic n = 549	Total n = 702	P values
Age, years	60 ± 9	60 ± 12	60 ± 11	NS
Male, n (%)	88 (57.5)	309 (56.3)	397 (56.6)	NS
Weight, kg	84 ± 17	75 ± 15	77 ± 15	<0.001
Height, cm	165 ± 8	167 ± 9	167 ± 9	NS
Systolic BP, mmHg	158 ± 13	160 ± 13	160 ± 13	0.03
Diastolic BP, mmHg	92 ± 9	95 ± 10	94 ± 10	<0.001
Pulse pressure, mmHg	66 ± 13	65 ± 14	65 ± 14	NS
Heart rate, bpm	75 ± 10	73 ± 10	73 ± 10	NS

Results are given as mean ± SD.

a)

global population

b)

hypertensive diabetic patients

c)

**hypertensive non diabetic patients**

Figure 1 Mean changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) compared with the baseline at V1 (4–6 weeks) and V2 (8–12 weeks) in the global population (a), hypertensive diabetic patients (b), and hypertensive non-diabetic patients (c) treated by CC 8–16 mg. Mean values are given, standard deviation is shown in parentheses.

compared with the baseline were more important in diabetic patients for SBP, DBP and PP values (p < 0.001) than in non-diabetic patients (Table 2). The mean changes in heart rate were not statistically significant between diabetic and non-diabetic patients.

Discussion

Previous studies have shown that antihypertensive agents may exert different effects on glycemic control. In general, ACE inhibitors, ARAs, and calcium channel blockers seem to have neutral or beneficial effects, whereas β-blockers and thiazide diuretics tend to worsen insulin resistance for glycemic control (Bengtsson et al 1984; Padwal and Laupacis 2004; Scheen 2004). However, studies have shown conflicting results, even between agents within the same classes (Padwal and Laupacis 2004). Rather than using surrogate blood pressure end points, with different antihypertensive agents, it may be more clinically relevant to examine the effect of the same treatment on controlling hypertensive diabetic and non-diabetic patients. Several trials have been conducted in diabetic patients comparing two or more drugs (Estacio et al 1998; UKPDS 39 1998; HOPE 2000; Lindholm et al 2000, 2002; Mogensen et al 2000; Niskanen et al 2001; Mancia et al 2003), or an active drug against placebo (SHEP Cooperative Research Group 1991; Trenkwalder et al 1998; Lithell et al 2003) but only few studies have evaluated blood pressure lowering using one drug in the same study comparing the effect in diabetic and non-diabetic patients (Jaichenko et al 1998; Preston et al 2001; Gottlieb et al 2003).

The present analysis pooled data of five randomized double-blind clinical trials (Denolle et al 2001; Imbs and Nisse-Durgeat 2005; Baguet et al 2006; Olivier JP, pers comm; Baguet JP, pers comm) with the objective of analyzing the effect of CC on diabetic and non-diabetic patients. The antihypertensive effect of CC 8–16 mg was observed by BP reduction achieved by 12 weeks in all patients treated.

BP values in diabetic hypertensive patients are usually higher than in non-diabetic patients despite the use of larger number of drugs (Estacio et al 1998; Jaichenko et al 1998; UKPDS 39 1998; HOPE 2000; Lindholm et al 2000, 2002; Brenner et al 2001; Lewis et al 2001; Niskanen et al 2001; Parving et al 2001; Gottlieb et al 2003; Lithell et al 2003; Mancia et al 2003). Indeed, treatment is accompanied by large BP reductions, but while achieved DBP is almost invariably well below 90 mmHg and even 80 mmHg, the concomitant SBP remained above 140 mmHg (Brenner et al 2001; Lewis et al 2001; Parving et al 2001; Lindolm et al 2002). Thus, in hypertensive diabetic patients treated with irbesartan 300 mg or amlodipine 10 mg, the final average SBP/DBP values were 140/77 mmHg and 141/77 mmHg respectively (Lewis et al 2001). Irbesartan 150 mg and irbesartan 300 mg administrated to hypertensive diabetic patients with nephropathy gave final SBP/DBP values of 143/83 and 141/83 mmHg, respectively (Parving et al 2001). Hypertensive diabetic patients treated by losartan achieved mean SBP/DBP final values of 140/74 mmHg vs placebo (Brenner et al 2001), and of 146/79 mmHg vs atenolol (Lindolm et al 2002).

In a previous study, CC 8–16 mg lowered SBP/DBP values to 149/89 mmHg compared with 151/90 with placebo (Trenkwalder et al 1998). In the present analysis, a more important reduction in mean SBP, DBP, and PP values was observed in diabetic (137/82/55 mmHg) compared with non-diabetic patients (143/84/59 mmHg).

Table 2 Blood pressure changes in diabetic and non-diabetic hypertensive patients

	Diabetic n = 153		Non-diabetic n = 549		
	Mean ± SD	Mean change ± SD	Mean ± SD	Mean change ± SD	p
V1[a]					
Systolic BP, mmHg	143 ± 17	−14 ± 14	146 ± 16	−14 ± 15	NS
Diastolic BP, mmHg	84 ± 10	−9 ± 10	86 ± 10	−9 ± 10	NS
Pulse pressure, mmHg	59 ± 12	−5 ± 11	60 ± 13	−10 ± 9	NS
Heart Rate, bpm	74 ± 9	−0.3 ± 7	73 ± 9	−0.2 ± 9	NS
V2[b]					
Systolic BP, mmHg	137 ± 15	−21 ± 15	143 ± 15	−17 ± 14	<0.001
Diastolic BP, mmHg	82 ± 9	−11 ± 9	84 ± 10	−10 ± 10	0.034
Pulse pressure, mmHg	55 ± 10	−10 ± 13	60 ± 13	−7 ± 13	<0.001
Heart rate, bpm	73 ± 9	−1.3 ± 7	72 ± 9	−1 ± 9	NS

Mean change values were obtained comparing with the baseline.
[a]V1: 4- to 6-week period of treatment with CC 8 mg once daily.
[b]V2: 8- to 12-week period of treatment with 8–16 mg once daily.

In spite of a good response to CC in BP lowering, the recommendations to lower SBP in diabetic patients to values below 130 mmHg were not totally achieved. The difference in the BP response between diabetic and non-diabetic patients may partly be explained by a physiological mechanisms differently acting in diabetic and non diabetic patients.

Several randomized clinical trials suggested that the inhibition of the renin-angiotensin (RA) system reduces the risk of new onset of type 2 diabetes mellitus (T2DM) in patients with arterial hypertension (Padwal and Laupacis 2004; Scheen 2004) or with congestive heart failure (Padwal and Laupacis 2004). Considering the pandemic of T2DM, such a pharmacological approach deserves further attention among the strategies aiming at preventing the disease. This preventive effect of the RA inhibition should involve the intimate mechanisms of the complex pathophysiology of T2DM. A Japanese study suggested that hypoadiponectinemia is related to insulin resistance in essential hypertension (Furuhashi et al 2003). It also showed that treatment with temocarpil or candesartan significantly decreases blood pressure and increased insulin-mediated glucose disposal and plasma adiponectin concentrations (Furuhashi et al 2003). These observations require further investigation.

Another possible mode of action has been hypothesized for ARBs. A recent study (Mancia and Grassi 2002) demonstrated that a subset of ARAs induces PPAR-γ activity by interaction with the PPAR-γ ligand binding domain. ARAs with PPAR-γ activating properties at low (telmisartan), medium (irbesartan), and very high concentrations (losartan) as well as a non-activating ARA (eposartan) have been identified. The authors concluded that molecules that can simultaneously block the ATII receptor and activate PPAR-γ have the potential to treat both hemodynamic and biochemical features.

CC has been useful in treating hypertensive patients who have experienced side-effects with other antihypertensive agents. Its good tolerability has been reported and favorable effects on target organ damage, morbidity, and mortality were achieved in long-term studies (Lithell et al 2003). The lower rate of new-onset diabetes mellitus reported in the CC group compared with the control group found in SCOPE is of the same magnitude as that observed in the other ARB losartan-treated group compared with the β-blocker treated group in the LIFE study (Lindholm et al 2002). A more favorable metabolic profile and a lower risk of developing diabetes in hypertensive patients treated with CC 16 mg was also described in the ALPINE study (Lindholm et al 2003).

CC has potential as initial treatment of hypertension and, as shown in the present analysis, CC was effective in diabetic as well as in non-diabetic patients, and furthermore, with a significant SBP, DBP, and PP lowering in diabetic patients. CC merits further investigation in diabetic patients.

Acknowledgments

References

Asmar R, Vol S, Pannier B, et al. 2001. High blood pressure and associated cardiovascular risk factors in France. *J Hypertens,* 19:1727–32.

Baguet JP, Nisse-Durgeat S, Mouret S, et al. 2006. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. *Int J Clin Pract,* 60:391–8.

Bakris GL, Douglas J, Dworkin L, et al. 2000. Treatment of hypertension in adults with diabetes to preserve renal function: a consensus approach endorsed by the Scientific Advisory Board of the National Kidney Foundation. *Am J Kidney Dis,* 36:646–61.

Bengtsson C, Blohme G, Lapidus L, et al. 1984. Do antihypertensive drugs precipitate diabetes? *Br Med J,* 289:1495–7.

Berne C, Pollare TG, Lithell H. 1991. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. *Diabetes Care,* 14:39–47.

Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. 2001. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med,* 345:861–9.

Chaudhry SI, Krumholz HM, Foody JM. 2004. Systolic hypertension in older person. *JAMA,* 292:1074–80.

Chobanian AV, Bakris GL, Black HR, et al. 2003. The Seventh Report of the Joint National Committee on Preventions, detection, evaluation, and Treatment of High Blood Pressure. *JAMA,* 289:560–571.

Denolle T, Vaisse B, Perie F, et al. 2001. Feasibility of ambulatory blood pressure and home blood pressure measurement in therapeutic trials. *Am J Hypertens,* 14:42A.

Estacio RO, Jeffers BW, Hiatt WR, et al. 1998. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *N Engl J Med,* 338:645–52.

Furuhashi M, Ura N, Higashiura K, et al. 2003. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. *Hypertension,* 42:76–81.

Gottlieb S, Leor J, Shotan A, et al. 2003. Comparison of effectiveess of angiotensin-converting enzyme inhibitors after acute myocardial infarction in diabetic versus nondiabetics patients. *Am J Cardiol,* 92:1020–5.

Guidelines Subcommittee. 1999. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. *J Hypertens,* 17:151–83.

Guidelines Committee. 2003. European Society of Hypertension—European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens,* 21:1011–53.

Hansson L, Zanchetti A, Carruthers SG, et al. 1998. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet,* 351:1755–62.

[HDSG] Hypertension in Diabetes Study Group: Hypertension in Diabetes Study (HDS). 1993. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. *J Hypertens,* 11:319–25.

Imbs JL, Nisse-Durgeat S; French Collaborative Candesartan Study Group. 2005. Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients. *Int J Clin Pract,* 59:78–84.

Jaichenko J, Fudin R, Shostak A, et al. 1998. Use of angiotensin-converting enzyme inhibitors in patients with diabetic and non diabetic chronic renal diseases: a need for reassessment. *Nephron,* 80:367–8.

Lewis EJ, Hunsicker LG, Clarke WR, et al. 2001. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med,* 345:851–60.

Lindholm LH, Hansson L, Ekbom T, et al. 2000. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. *J Hypertens,* 18:1671–5.

Lindholm LH, Ibsen H, Dahlof B, et al. 2002. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet,* 359:1004–10.

Lindholm LH, Pearson M, Alaupovic P, et al. 2003. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). *J Hypertens,* 21:1563–74.

Lithell H, Hanson L, Skoog I, et al. 2003. The study on cognition and prognosis in the elderly (SCOPE): principle results of a randomized double-blind intervention trial. *J Hypertens,* 21:875–86.

Mancia G, Grassi G. 2002. Systolic and diastolic blood pressure control in antihypertensive drug trials. *J Hypertens,* 20:1461–4.

Mogensen CE, Neldam S, Tikknen I, et al. 2000. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. *BMJ,* 321:1440–4.

Mancia G, Broun M, Castaigne A, et al. 2003. Outcomes with nifeldipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT). *Hypertension,* 41:431–6.

Niskanen L, Hedner T, Hansson L, et al.; CAPPP Study Group. 2001. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment: a sub-analysis of the Captopril Prevention Project. *Diabetes Care,* 24:2091–6.

Oksa A, Gajdos M, Fedelesova V, et al. 1994. Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. *J Cardiovasc Pharmacol,* 23:79–86.

Padwal R, Laupacis A. 2004. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. *Diabetes Care,* 27:247–55.

Parving HH, Lehnert H, Brochner-Mortensen J, et al. 2001. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med,* 34:870–8.

Pershadsingh HA, Kurtz TW. 2004. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. *Diabetes Care,* 27:1015.

Pollare TG, Lithell H, Berne C. 1989. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. *N Engl J Med,* 321:868–73.

Preston RA, Chung M, Gaffney M, et al. 2001. Comparative pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with and without type II diabetes mellitus. *J Clin Pharmacol,* 41:1215–24.

Scheen AJ. 2004. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. *Drugs,* 64:2537–65.

SHEP Cooperative Research Group. 1991. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA,* 265:3255–64.

Stamler J, Vaccaro O, Neaton JD, et al. 1993. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care,* 16:434–44.

Staessen JA, Fagard R, Thijs L, et al. 1997. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. *Lancet,* 350:757–64.

Trenkwalder P, Dahl K, Lehtovirta M, et al. 1998. Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. *Blood Press,* 7:170–5.

Trost BN, Weidmann P. 1987. Effects of calcium antagonists on glucose homeostasis and serum lipids in non–diabetic and diabetic subjects: a review. *J Hypertens,* 5 (Suppl):S81–104.

[UKPD 33] UK Prospective Diabetes Study Group 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet,* 352:837–53.

[UKPD 34] UK Prospective Diabetes Study Group. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet,* 352:854–65.

[UKPD 34] UK Prospective Diabetes Study Group. 1998. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). *BMJ,* 317:703–13.

[UKPDS 39] UK Prospective Diabetes Study Group. 1998. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). *BMJ,* 317:713–21.